Pimitespib

Phase 1Small molecule

Taiho Pharmaceutical Co., Ltd.

Pimitespib is one of 7 small molecule programs targeting GIST. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

GISTActive, not recruiting

GISTPhase 1

Active, not recruiting

Competition

Competitive Landscape

6 competitors in GIST

#DrugCompanyPhaseTrials

Gleevec

Novartis

Approved

5 2

Luye

Ascentage Pharma Group Inc.

Phase 3

1 3

Pemazyre

Incyte

Phase 2

1 4

Sutent

Pfizer

Phase 1

3 5

Qinlock

DDeciphera Pharmaceuticals, LLC

Preclinical

1 6

Pimitespib

Taiho Pharmaceutical Co., Ltd.

Phase 1

1 7

Inlexisertib

DDeciphera Pharmaceuticals, LLC

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Active, not recruiting

GIST

NCT05245968

Clinical

Trials by Indication[1]

GIST1 trial

A Study of Pimitespib in Combination With Imatinib in Patients With GIST (CHAPTER-GIST-101)

Active, not recruiting· Taiho Pharmaceutical Co., Ltd. logo

Taiho Pharmaceutical Co., Ltd.·Phase 1·NCT05245968·78 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Pimitespib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Pimitespib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Pimitespib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Taiho Pharmaceutical Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Taiho Pharmaceutical Co., Ltd.

Pimitespib

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

GIST1 trial

References

Drug Info

Quick Facts

Related News